Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures

Journal of Neurochemistry

Volumn 112, Issue 6, 2010, Pages 1477-1487

  Lee, Eun Ok ^a   Park, Hee Ju ^a   Kang, Jihee Lee ^a   Kim, Hye Sun ^b   Chong, Young Hae ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Alzheimer's disease; Extracellular signal regulated kinase 1 2; Glutamate; Interleukin 1 ; Monocyte chemoattractant protein 1; Resveratrol

Indexed keywords

ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; GLUTAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; RESVERATROL;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENCEPHALITIS; ENZYME INACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

RATTUS;

EID: 77349084145     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06564.x     Document Type: Article

References (51)

1. 2 in acute hippocampal slice preparations from Wistar rats. Arch. Biochem. Biophys. 480, 27 32.
2. Ates O., Cayli S. R., Yucel N., Altinoz E., Kocak A., Durak M. A., Turkoz Y. Yologlu S. (2007) Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J. Clin. Neurosci. 14, 256 260.
3. Baudry M. Lynch G. (2001) Remembrance of arguments past: how well is the glutamate receptor hypothesis of LTP holding up after 20 years? Neurobiol. Learn. Mem. 76, 284 297.
4. Bellizzi M. J., Lu S. M. Gelbard H. A. (2006) Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J. Neuroimmune. Pharmacol. 1, 20 31.
5. Betzen C., White R., Zehendner C. M., Pietrowski E., Bender B., Luhmann H. J. Kuhlmann C. R. (2009) Oxidative stress upregulates the NMDA receptor on cerebrovascular endothelium. Free Radic. Biol. Med. 47, 1212 1220.
6. Blander G. Guarente L. (2004) The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417 435.
7. Brodmerkel C. M., Huber R., Covington M. et al. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 175, 5370 5378.
8. Carlsson C. M. (2008) Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions. J. Alzheimers Dis. 15, 327 338.
9. Chang L., Ernst T., St Hillaire C. Conant K. (2004) Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir. Ther. 9, 431 440.
10. Chen Y., Hallenbeck J. M., Ruetzler C., Bol D., Thomas K., Berman N. E. Vogel S. N. (2003) Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab. 23, 748 755.
11. Chong Y. H., Shin Y. J., Lee E. O., Kayed R., Glabe C. G. Tenner A. J. (2006) ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J. Biol. Chem. 281, 20315 20325.
12. Cullen J. P., Morrow D., Jin Y., Curley B., Robinson A., Sitzmann J. V., Cahill P. A. Redmond E. M. (2007) Resveratrol, a polyphenolic phytostilbene, inhibits endothelial monocyte chemotactic protein-1 synthesis and secretion. J. Vasc. Res. 44, 75 84.
13. Denker S. P., Ji S., Dingman A., Lee S. Y., Derugin N., Wendland M. F. Vexler Z. S. (2007) Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J. Neurochem. 100, 893 904.
14. Francis P. T. (2005) The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr. 10, 6 9.
15. Galimberti D., Fenoglio C., Lovati C. et al. (2006a) Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging 27, 1763 1768. (Pubitemid 44572579)
16. Galimberti D., Schoonenboom N., Scheltens P. et al. (2006b) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63, 538 543.
17. Grammas P. Ovase R. (2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22, 837 842.
18. Han Y. S., Zheng W. H., Bastianetto S., Chabot J. G. Quirion R. (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. 141, 997 1005.
19. Handattu S. P., Garber D. W., Monroe C. C. et al. (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis. 34, 525 534.
20. Henkel J. S., Beers D. R., Siklós L. Appel S. H. (2006) The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31, 427 437.
21. Holopainen I. E. (2005) Organotypic hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, neuroprotection, and synaptic plasticity. Neurochem. Res. 30, 1521 1528.
22. Howitz K. T., Bitterman K. J., Cohen H. Y. et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191 196.
23. Ishizuka K., Kimura T., Igata-yi R., Katsuragi S., Takamatsu J. Miyakawa T. (1997) Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin. Neurosci. 51, 135 138.
24. Kang O. H., Jang H. J., Chae H. S. et al. (2009) Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol. Res. 59, 330 337.
25. Karuppagounder S. S., Pinto J. T., Xu H., Chen H. L., Beal M. F. Gibson G. E. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 54, 111 118.
26. Katayama T., Ito M., Kaneko S., Satoh M., Uehara T. Minami M. (2009) Reciprocal regulation of ATPgammaS-induced monocyte chemoattractant protein-1 production by ERK and p38 MAP kinases in rat corticostriatal slice cultures. J. Neurosci. Res. 87, 1573 1581.
27. Kuhle J., Lindberg R. L., Regeniter A., Mehling M., Steck A. J., Kappos L. Czaplinski A. (2009) Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16, 771 774.
28. Lee J. H., Lee E. O., Kang J. L. Chong Y. H. (2008) Concomitant degradation of beta-catenin and GSK-3 beta potently contributes to glutamate-induced neurotoxicity in rat hippocampal slice cultures. J. Neurochem. 106, 1066 1077.
29. Lim J. H. Kwon T. K. (2009) Curcumin inhibits phorbol myristate acetate (PMA)-induced MCP-1 expression by inhibiting ERK and NF-kappaB transcriptional activity. Food Chem. Toxicol. 48, 47 52.
30. Lindsay J., Laurin D., Verreault R., Hébert R., Helliwell B., Hill G. B. McDowell I. (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156, 445 453.
31. Lipton S. A. (2005) The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2, 155 165.
32. Madrigal J. L., Leza J. C., Polak P., Kalinin S. Feinstein D. L. (2009) Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 29, 263 267.
33. Mattson M. P. (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N Y Acad. Sci. 1144, 97 112.
34. Ono K., Matsumori A., Furukawa Y., Igata H., Shioi T., Matsushima K. Sasayama S. (1999) Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab. Invest. 79, 195 203.
35. Pallàs M., Casadesús G., Smith M. A., Coto-Montes A., Pelegri C., Vilaplana J. Camins A. (2009) Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr. Neurovasc. Res. 6, 70 81.
36. Park D. W., Baek K., Kim J. R., Lee J. J., Ryu S. H., Chin B. R. Baek S. H. (2009) Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp. Mol. Med. 41, 171 179.
37. Penumathsa S. V. Maulik N. (2009) Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can. J. Physiol. Pharmacol. 87, 275 286.
38. Pineau I. Lacroix S. (2008) Endogenous signals initiating inflammation in the injured nervous system. Glia 57, 351 361.
39. Pliss L., Jezova D., Mares V., Balcar V. J. St'astny F. (2002) N-acetyl-l-aspartyl-l-glutamate changes functional and structural properties of rat blood-brain barrier, Neurosci. Letter 317, 85 88.
40. Ramassamy C. (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerativediseases: a review of their intracellular targets. Eur. J. Pharmacol. 545, 51 64.
41. Sastre M., Klockgether T. Heneka M. T. (2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24, 167 176.
42. Schilling M., Strecker J. K., Schäbitz W. R., Ringelstein E. B. Kiefer R. (2009) Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 161, 806 812.
43. Shakibaei M., Harikumar K. B. Aggarwal B. B. (2009) Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res. 53, 115 128.
44. Simard A., Soulet D., Gowing G., Julien J. Rivest S. (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489 502.
45. Sokolova A., Hill M. D., Rahimi F., Warden L. A., Halliday G. M. Shepherd C. E. (2009) Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol. 19, 392 398.
46. Tanuma N., Sakuma H., Sasaki A. Matsumoto Y. (2006) Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 112, 195 204.
47. Thompson W. L. Van Eldik L. J. (2009) Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-7 through NFkappaB and MAPK dependent pathways in rat astrocytes. Brain Res. 1287, 47 57.
48. Ubogu E. E., Cossoy M. B. Ransohoff R. M. (2006) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27, 48 55.
49. Vukic V., Callaghan D., Walker D. et al. (2009) Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34, 95 106.
50. Wang J. Q., Fibuch E. E. Mao L. (2007) Regulation of mitogen-activated protein kinases by glutamate receptors. J. Neurochem. 100, 1 11.
51. Yousuf S., Atif F., Ahmad M., Hoda N., Ishrat T., Khan B. Islam F. (2009) Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 250, 242 253.